Page last updated: 2024-12-10
methyl hesperidin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
methyl hesperidin : A flavanone glycoside that is hesperidin in which the hydroxy group at position 3' has been replaced by a methoxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5284419 |
| CHEMBL ID | 3184988 |
| CHEBI ID | 81056 |
| MeSH ID | M0147894 |
Synonyms (31)
| Synonym |
|---|
| 11013-97-1 |
| (2s)-2-[3,4-bis(methyloxy)phenyl]-5-hydroxy-4-oxo-3,4-dihydro-2h-chromen-7-yl 6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside |
| methyl hesperidin |
| 4h-1-benzopyran-4-one, 7-((6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, monomethyl ether, (2s)- |
| methylhesperidin |
| ccris 4278 |
| AC-11572 |
| C17393 |
| A802151 |
| (2s)-2-(3,4-dimethoxyphenyl)-5-hydroxy-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chroman-4-one;methyl-hesperidin |
| NCGC00249210-01 |
| (2s)-2-(3,4-dimethoxyphenyl)-5-hydroxy-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one |
| NCGC00256545-01 |
| tox21_302739 |
| cas-11013-97-1 |
| dtxcid90841 |
| dtxsid7020841 , |
| tox21_202328 |
| NCGC00259877-01 |
| unii-k324u7386b |
| k324u7386b , |
| AKOS015960520 |
| 4h-1-benzopyran-4-one, 7-((6-o-(6deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3,4-dimethoxyphenyl)-, (2s)- |
| methyl hesperidin [inci] |
| methyl hesperidin [who-dd] |
| 4h-1-benzopyran-4-one, 7-((6-o-(6deoxy-.alpha.-l-mannopyranosyl)-.beta.-d-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, monomethyl ether, (2s)- |
| CHEBI:81056 , |
| (2s)-2-(3,4-dimethoxyphenyl)-5-hydroxy-4-oxo-3,4-dihydro-2h-1-benzopyran-7-yl 6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside |
| CHEMBL3184988 |
| Q27155011 |
| (s)-2-(3,4-dimethoxyphenyl)-5-hydroxy-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-((((2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)methyl)tetrahydro-2h-pyran-2-yl)oxy)chroman-4-one |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (7)
| Class | Description |
|---|---|
| monohydroxyflavanone | Any hydroxyflavanone carrying a single hydroxy substituent. |
| dimethoxyflavanone | A methoxyflavanone that is flavanone with two methoxy substituents. |
| disaccharide derivative | A carbohydrate derivative that is formally obtained from a disaccharide. |
| flavanone glycoside | A member of the class of flavanones having one or more glycosyl residues attached at unspecified positions. |
| rutinoside | |
| 4'-methoxyflavanones | Any methoxyflavanone having a methoxy substituent located at position 4'. |
| 3'-methoxyflavanones | Any methoxyflavanone having a methoxy substituent located at position 3'. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 65.7703 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 18.8139 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 23.4931 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 29.5761 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 5.9495 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 30.54
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.54) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||